Shenzhen Synthetica Pioneering Co., Ltd. has successfully concluded a Series A funding round, raising significant capital to propel its innovative oncolytic bacterial therapy into clinical trials. This funding milestone, spearheaded by prominent investors including Boehringer Ingelheim Venture Fund and Temasek, along with contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund, underscores the growing confidence in Synthetica’s pioneering approach to cancer treatment.
Founded in 2023 and headquartered in Shenzhen, Synthetica is at the forefront of synthetic biology, specializing in the engineering of bacterial therapeutics designed to tackle solid tumors. With its roots deeply embedded in the Shenzhen Institute of Advanced Technology (SIAT) and the Chinese Academy of Sciences (CAS), the company utilizes cutting-edge genetic circuit engineering to create precise and effective treatments that promise to redefine cancer care.
Yingke He, CEO of Synthetica, remarked on this significant development: “This funding is a game-changer for us, marking a critical juncture in our mission to advance cancer treatment. Our synthetic biology techniques in developing oncolytic bacteria offer a novel and promising approach to more effective and targeted therapies. We extend our deepest gratitude to our investors and technology partners for their invaluable support. With this backing, we are poised to make substantial strides in transforming cancer treatment and improving patient outcomes globally.”
Dr. Mia Hu, Investment Director at Boehringer Ingelheim Venture Fund, highlighted the strategic importance of this investment: “At Boehringer Ingelheim Venture Fund, we are dedicated to supporting groundbreaking therapeutics that address critical patient needs. Oncolytic bacterial therapy represents a pivotal area for us, and Synthetica’s team, with their exceptional expertise in quantitative synthetic biology, is breaking new ground in this field. We are excited to be part of this journey and eager to see how their innovative approach will advance the treatment of solid tumors.”
Editorial Perspective:
Synthetica Pioneering’s breakthrough in oncolytic bacterial therapy represents a significant leap forward in the fight against cancer. By leveraging synthetic biology to engineer bacterial treatments, Synthetica is addressing a crucial gap in current cancer therapies. The company’s focus on solid tumors, which have historically been challenging to treat, is particularly noteworthy. This approach not only aims to enhance efficacy but also seeks to minimize invasiveness, offering new hope to patients with limited options.
The involvement of high-profile investors such as Boehringer Ingelheim Venture Fund and Temasek underscores the confidence in Synthetica’s innovative approach and its potential to impact global cancer treatment paradigms. With the Series A funding now secured, Synthetica is well-positioned to accelerate its research and development efforts, transitioning from the laboratory to clinical settings where it can make a tangible difference in patients’ lives.
The company’s emphasis on combining advanced synthetic biology techniques with practical therapeutic applications highlights a forward-thinking strategy that aligns with current trends in precision medicine. As Synthetica moves closer to clinical trials, the biotech community and patients alike will be watching with great interest. Their progress could very well set new standards in cancer treatment and pave the way for more effective, targeted therapies in the future.
For additional information or inquiries, please contact editor@thetimesmag.com.
